Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

PG-033

Small molecule · developed by Prime Gene Therapeutics Co.

Phase 1 Most advanced trial

PRME Developer

2 Registered trials

What is PG-033?

PG-033 is an investigational small-molecule drug studied in Lichen Simplex Chronicus.

At a glance

Drug type: Small molecule
Therapy area: Dermatology
Developer: Prime Gene Therapeutics Co., Ltd. (PRME)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT07619183	Phase 1	Lichen Simplex Chronicus	Not yet recruiting	PRME
NCT07013097	Phase 1	Lichen Simplex Chronicus	Recruiting	PRME

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Lichen Simplex Chronicus

More from Prime Gene Therapeutics Co.

PG-011 Phase 3 PG-011Gel Phase 3 PM359 Phase 1/2 PM577a Phase 1/2 Pumecitinib Phase 2

Sources

Updated Oct 3, 2026. Something wrong or missing? Report it on the PRME page.

Follow PRME, the company behind PG-033

See PRME's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

PRME catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z